Can I Take St. John's Wort With Spironolactone?

The Short Answer: No, These Two Should Not Be Combined

St. John's Wort (Hypericum perforatum) and spironolactone should not be taken together without direct guidance from your prescribing clinician. The concern is not theoretical. St. John's Wort is one of the most well-documented herbal inducers of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), two of the body's primary drug-clearance mechanisms. Spironolactone and its active metabolite canrenone are processed through these same pathways.

The result: your body may clear spironolactone faster than intended, leaving you with lower drug levels than your dose suggests.

Why This Matters More for Women

Women prescribed spironolactone are almost always using it off-label for hormone-driven conditions: acne, hirsutism, PCOS, or female pattern hair loss. The drug's therapeutic window for these indications is dose-dependent, typically 25 mg to 200 mg daily. Anything that silently lowers circulating drug levels can erode weeks of symptom control without an obvious explanation. You might assume the drug stopped working, when in fact the supplement is the problem.

St. John's Wort is also popular for mood support, particularly in perimenopause, when depression and anxiety rates rise sharply. That overlap between the women most likely to be on spironolactone and the women most likely to reach for St. John's Wort is real, and it is why clinicians specifically need to ask about herbal use.

How the Interaction Works: Pharmacokinetics, Not Just Theory

CYP3A4 Induction Is the Core Mechanism

The main active compounds in St. John's Wort, particularly hyperforin, are potent inducers of CYP3A4 as reviewed in this 2004 Clinical Pharmacokinetics paper indexed on PubMed. CYP3A4 is responsible for the metabolism of an estimated 50% of all prescription drugs. Spironolactone is converted hepatically to its active metabolites, canrenone and 7-alpha-spirolactone, via CYP3A4 and related enzymes.

When St. John's Wort upregulates CYP3A4, those metabolic pathways become more active. Spironolactone moves through your liver faster. Peak plasma concentration (Cmax) falls. The area under the curve (AUC), which represents your total drug exposure over time, shrinks. You are effectively getting less drug per dose than your prescription label says.

P-Glycoprotein Adds Another Layer

St. John's Wort also induces P-glycoprotein (P-gp), a membrane transporter that pumps drugs out of cells and back into the gut lumen before they reach systemic circulation. This reduces oral bioavailability of affected drugs. A landmark Lancet study published in 2000 documented this mechanism clearly in the context of cyclosporine, and subsequent research confirmed P-gp induction as a class effect of hyperforin-containing preparations.

Spironolactone has not been studied in a dedicated clinical pharmacokinetic interaction trial with St. John's Wort. This is the evidence gap you need to know about. The interaction is inferred mechanistically from spironolactone's known metabolic profile and St. John's Wort's well-characterized enzyme induction. That extrapolation is clinically sound, but direct human data comparing plasma levels of spironolactone with and without St. John's Wort co-administration does not yet exist.

The Potassium Problem: A Pharmacodynamic Layer

Beyond drug clearance, there is a second concern that sits on top of the pharmacokinetic issue. Spironolactone is a potassium-sparing diuretic and aldosterone antagonist. It raises serum potassium. At doses above 100 mg/day, clinically significant hyperkalemia occurs in roughly 2-3% of otherwise healthy young women, with higher rates in women who have kidney disease or who are combining spironolactone with ACE inhibitors or NSAIDs.

St. John's Wort does not have a strong direct effect on potassium. The risk here is indirect: if St. John's Wort reduces spironolactone levels, a prescriber may increase the dose in response to poor symptom control, potentially pushing toward a range where hyperkalemia risk climbs.

Who Is Prescribing Spironolactone to Women, and Why

Hormonal Acne and Hirsutism

Spironolactone blocks androgen receptors in the skin and reduces 5-alpha-reductase activity. For women with adult acne driven by androgen excess, it is one of the most commonly used off-label treatments. A 2017 JAMA Dermatology study found that spironolactone at 100 mg/day produced a 66% reduction in acne lesion count over 12 months. Doses typically range from 50 mg to 150 mg/day for this indication.

PCOS

Women with polycystic ovary syndrome (PCOS) carry a significant androgen burden. Spironolactone reduces free testosterone and is used to treat hirsutism, acne, and sometimes androgenic alopecia in this population. The Endocrine Society's 2023 PCOS guidelines list spironolactone as a recommended treatment option for hirsutism in women who do not desire pregnancy.

Perimenopausal Women

Perimenopause does not end androgen sensitivity. Some women experience a relative androgen excess during the menopause transition as estrogen falls faster than testosterone. Late-onset acne or worsening hirsutism in your 40s or early 50s may reflect this shift, and spironolactone prescriptions in this age group have increased. Perimenopausal women are also the group most likely to use St. John's Wort for mood symptoms, which is exactly where the prescribing overlap concentrates.

The St. John's Wort and Oral Contraceptive Problem: Double Jeopardy

This matters specifically for reproductive-age women on spironolactone. Because spironolactone carries a risk of feminizing a male fetus (see pregnancy section below), effective contraception is required whenever a woman with pregnancy potential is taking it. Many clinicians prescribe an oral contraceptive pill (OCP) alongside spironolactone.

St. John's Wort is one of the best-documented herbal reducers of OCP efficacy. The FDA issued a public health advisory on this interaction noting that St. John's Wort can reduce ethinyl estradiol levels by 15-20% and progestin levels by a similar margin, increasing breakthrough bleeding and contraceptive failure risk.

If you are taking spironolactone plus an OCP for contraception and you add St. John's Wort, you may be undermining both drugs simultaneously: reducing spironolactone's therapeutic effect AND reducing your contraceptive protection. This is a particularly consequential double effect.

The WomanRx Three-Way Conflict Framework for This Drug Combination:

| Drug or Supplement | What St. John's Wort Does to It | Clinical Consequence for Women | |---|---|---| | Spironolactone | Induces CYP3A4 and P-gp, lowering plasma levels | Reduced acne clearance, PCOS symptom control, or hirsutism improvement | | Ethinyl estradiol (OCP) | Induces CYP3A4, reduces hormone levels 15-20% | Contraceptive failure; critical risk given spironolactone teratogenicity | | Potassium balance | Indirect risk via dose escalation response | Prescriber may raise spironolactone dose, increasing hyperkalemia risk |

Pregnancy, Lactation, and Contraception: A Required Section

Spironolactone in Pregnancy

Spironolactone is contraindicated in pregnancy. Animal studies show anti-androgenic effects on male fetal development at doses relevant to human use. The drug has historically been assigned FDA Pregnancy Category C/D (older classification) and carries a known risk of feminizing the genitalia of a male fetus through androgen receptor blockade.

If you become pregnant while on spironolactone, stop it immediately and call your prescriber. Because the teratogenic risk is specifically to male fetuses during the first trimester period of genital differentiation, the concern is front-loaded in early pregnancy, before many women even have a confirmed result.

Contraception Requirement

ACOG recommends that all women of reproductive potential taking spironolactone use reliable contraception. Acceptable options include combined oral contraceptives (though these also have the St. John's Wort interaction problem noted above), levonorgestrel or copper IUDs, implants, or other highly effective non-hormonal methods.

If St. John's Wort reduces the effectiveness of your hormonal contraception, your contraceptive protection while on spironolactone is genuinely at risk. This is not a theoretical concern, and it is one of the most clinically urgent reasons to avoid this combination.

Lactation

Spironolactone and its active metabolite canrenone are detected in breast milk. A published pharmacokinetic study found that the relative infant dose is low, estimated at less than 2% of the maternal dose, which is generally below the threshold of clinical concern. The drug has been used with monitoring in breastfeeding women, but your prescriber should weigh the indication against potential effects on an infant's electrolyte balance.

St. John's Wort is also present in breast milk. A 2000 review published in the American Journal of Obstetrics and Gynecology found detectable hyperforin in the milk of nursing women, with colic and drowsiness reported in some infants. Using both together while breastfeeding adds risk without established safety data.

What to Do If You Are Already Taking Both

First: do not stop either drug abruptly before speaking with your clinician. Stopping spironolactone suddenly is generally safe, but stopping a mood supplement without a plan if you have been using it for depression support should be done with guidance.

A practical conversation with your prescriber should cover:

• How long you have been taking St. John's Wort (induction builds over one to two weeks and wanes over a similar period after discontinuation)
• Whether your acne, PCOS symptoms, or hirsutism has seemed less controlled recently (a possible clue that drug levels have dropped)
• What evidence-based alternatives to St. John's Wort exist for your mood concerns, such as SSRIs, which do not share the CYP3A4 induction profile
• Whether a serum potassium check is warranted if your dose has been adjusted recently

There is no validated dose-separation window that resolves this interaction. St. John's Wort's mechanism is enzyme induction, not competitive binding at a receptor. You cannot simply take them four hours apart and avoid the problem. The induction is systemic and persistent across the dosing day.

Alternatives to St. John's Wort for Women on Spironolactone

If you are on spironolactone and looking for mood or anxiety support, several options carry a cleaner interaction profile:

For mild to moderate depression or anxiety:

• SSRIs such as sertraline or escitalopram are not CYP3A4 inducers. A Cochrane review found SSRIs superior to placebo for mild to moderate depression and they are commonly used in perimenopause.
• Cognitive behavioral therapy (CBT) has comparable efficacy to antidepressants for mild depression in multiple trials.

For perimenopausal mood symptoms specifically:

• Hormone therapy (HT) addresses the root hormonal fluctuation driving perimenopausal mood changes and does not interfere with spironolactone's CYP pathway. The Menopause Society's 2022 position statement supports HT for perimenopausal women without contraindications.
• Magnesium glycinate at 200-400 mg/day has some evidence for anxiety reduction and does not induce CYP enzymes.

For sleep:

• Melatonin at 0.5-3 mg is not a CYP3A4 inducer and has no documented interaction with spironolactone.

None of these are prescribed here as clinical advice. They are starting points for a conversation with your prescriber.

What the Evidence Gap Actually Means for You

No randomized controlled trial has measured spironolactone plasma levels in women co-administered St. John's Wort versus placebo. This is an important caveat. The interaction is mechanistically well-founded, it is listed in major drug interaction databases, and the individual components (St. John's Wort as CYP3A4 inducer; spironolactone as a CYP3A4 substrate) are each well-characterized. But the specific magnitude of the reduction in spironolactone AUC in a woman taking 100 mg/day for acne is not documented in a published human trial.

As reviewed in a 2019 British Journal of Clinical Pharmacology analysis of herb-drug interactions, CYP3A4 induction by St. John's Wort reduces substrate drug AUC by a median of approximately 50% across studied drugs, with a range of 20-70% depending on the specific substrate and formulation of the herb used. Applying that range to spironolactone is extrapolation, but it is clinically meaningful extrapolation.

Women have historically been underrepresented in pharmacokinetic drug interaction studies. Much of the CYP3A4 induction data that exists was generated in male subjects or mixed-sex cohorts where female-specific data was not reported separately. Whether follicular-phase versus luteal-phase hormonal status alters the magnitude of St. John's Wort's CYP3A4 induction in women is not known. This is a genuine evidence gap, and it means current clinical guidance is built on extrapolation from male-dominated datasets.

Monitoring: What Your Clinician Should Check

If you have been taking both and your clinician decides a transition plan is needed rather than immediate discontinuation of St. John's Wort:

• Serum potassium: Baseline and repeat in four to six weeks after any dose change of spironolactone, particularly if your dose is at or above 100 mg/day. Normal serum potassium is 3.5-5.0 mEq/L; hyperkalemia risk with spironolactone becomes clinically significant above 5.0 mEq/L.
• Blood pressure: Spironolactone lowers blood pressure. If levels drop due to CYP induction and your prescriber raises the dose, then the supplement is later stopped, circulating drug levels may rise unexpectedly, increasing hypotension risk.
• Renal function (creatinine, eGFR): Required at baseline and periodically during spironolactone use per standard monitoring, particularly relevant if you are in perimenopause with declining renal reserve.
• Menstrual cycle tracking: Spironolactone affects the hypothalamic-pituitary-ovarian axis and can cause irregular bleeding. Women on spironolactone alone frequently report cycle changes. If St. John's Wort is altering levels, you may notice changes in breakthrough bleeding patterns as a proxy signal.

Who Should Be Especially Careful

Some women face a higher risk from this combination and should be particularly direct with their prescriber:

Women with PCOS who depend on spironolactone for both acne and androgen control, where even modest reductions in drug exposure can set back months of symptom management.

Women in perimenopause who may be on spironolactone for late-onset acne or hirsutism and are simultaneously seeking mood support. This is the group most at risk of the combination occurring without clinical oversight.

Women on combined OCP plus spironolactone as a standard dual-purpose regimen (contraception plus acne control), where St. John's Wort threatens both drugs at once.

Women with any kidney impairment, where spironolactone's potassium-sparing effect is already amplified and potassium shifts are less predictable.

Women on any other CYP3A4-sensitive medication, including some antiretrovirals, antifungals, or certain antidepressants, where adding a potent inducer compounds the interaction burden.